MedPath

Tagged News

Mythic Therapeutics' MYTX-011 Shows Promising Efficacy in Phase 1 Trial for Advanced NSCLC

OncologyTargeted Therapy
  • Mythic Therapeutics will present updated dose escalation data from its Phase 1 KisMET-01 study of MYTX-011, a cMET-targeting antibody-drug conjugate, at the 2025 ASCO Annual Meeting.
  • The preliminary results demonstrate meaningful anti-tumor activity in cMET-positive non-small cell lung cancer patients across various cMET expression levels, histologies, and genetic alterations.
  • MYTX-011 leverages Mythic's proprietary FateControl™ technology, designed to enhance ADC uptake in tumor cells while minimizing impact on healthy tissues.

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

NCT05652868RecruitingPhase 1
Mythic Therapeutics
Posted 3/23/2023

Dual-Targeting Radiopharmaceutical Shows 89% Response Rate in Advanced Cancer Trial

Targeted Therapy
  • A novel dual-targeting radiopharmaceutical therapy targeting two cancer cell markers simultaneously demonstrated safety and efficacy in a first-in-human trial with nine advanced adenocarcinoma patients.
  • The treatment achieved an 88.9% response rate, with patients experiencing either tumor shrinkage or disease stabilization after a single treatment cycle.
  • The therapy showed strong tumor uptake lasting for days, allowing prolonged radiation damage to cancer cells while causing no noticeable side effects.
  • Patients reported significant quality of life improvements including reduced pain, better appetite, and overall symptom relief compared to previous treatments.

Servier to Present Phase 3 Data on IDH-Mutated Cancer Therapies at ASCO 2025

Precision MedicineTargeted TherapyOncology
  • Servier will showcase its precision medicine research for IDH-mutated cancers at the 2025 ASCO Annual Meeting in Chicago, focusing on chondrosarcoma, cholangiocarcinoma, and myelodysplastic syndrome.
  • The company, which allocates over 65% of its R&D budget to oncology, will present updates on several Phase 3 programs aimed at developing new treatment options for patients with IDH-mutated cancers.
  • As a global leader in IDH-mutant targeted therapies, Servier's presentations will reinforce its commitment to advancing precision medicine through mutation identification and understanding cancer progression mechanisms.

Rigel Pharmaceuticals Unveils Promising Final Data from GAVRETO and REZLIDHIA Clinical Trials at ASCO and EHA 2025

OncologyTargeted TherapyPrecision Medicine
  • Final data from the Phase 1/2 ARROW study demonstrates GAVRETO's durable efficacy in RET fusion-positive NSCLC, with a 70.3% overall response rate and median overall survival of 44.3 months.
  • GAVRETO shows promising anti-tumor activity in various RET fusion-positive solid tumors beyond lung cancer, including a 100% response rate in pancreatic cancer patients.
  • REZLIDHIA data supports its potential clinical benefit when used in earlier treatment lines for relapsed/refractory AML patients and as maintenance therapy, with particularly strong outcomes in patients with fewer prior therapies.

FORE Biotherapeutics Secures $38 Million in Series D-2 Financing to Advance Plixorafenib Clinical Trials

Targeted TherapyOncologyPrecision Medicine
  • FORE Biotherapeutics has raised $38 million in Series D-2 financing to advance its global Phase 2 FORTE Master Protocol evaluating plixorafenib across multiple BRAF-mutated cancer indications.
  • The company anticipates interim analyses in 2025 across three monotherapy indications: BRAF V600 primary recurrent CNS tumors, rare BRAF V600 mutated solid tumors, and advanced solid tumors with BRAF fusions.
  • Plixorafenib, designed with a first-in-class mechanism to address limitations of earlier BRAF inhibitors, has previously demonstrated promising efficacy with a 67% overall response rate in BRAF V600 primary recurrent CNS tumors.

Peptide Drug Conjugates Emerge as Next-Generation Cancer Therapeutics with Over 30 Candidates in Clinical Development

Targeted TherapyOncologyDrug Approval
  • Peptide drug conjugates represent a novel targeted therapy approach that combines disease-targeting peptides with small molecule drugs to deliver treatments directly to diseased tissues while minimizing systemic toxicity.
  • The global peptide drug conjugate market has experienced remarkable growth of over 300% absolute growth and 27% CAGR from 2018-2024, with market opportunities exceeding $1.4 billion.
  • Two peptide drug conjugates have received regulatory approval as of May 2025: Novartis's Lutathera for gastroenteropancreatic neuroendocrine tumors and Oncopeptides' Pepaxti for multiple myeloma.
  • More than 30 peptide drug conjugate candidates are currently advancing through various stages of clinical trials, primarily focused on oncology applications but expanding into neurodegenerative and inflammatory disorders.

NeoGenomics Launches c-MET Companion Diagnostic for Advanced Non-Small Cell Lung Cancer Treatment

Targeted TherapyDrug ApprovalOncologyPrecision Medicine
  • NeoGenomics has commercially launched c-MET CDx for NSCLC, a companion diagnostic assay that detects c-Met protein overexpression in advanced non-small cell lung cancer patients with a 48-hour turnaround time.
  • The diagnostic test supports patient selection for newly FDA-approved targeted therapy EMRELIS™ (telisotuzumab vedotin-tllv), offering a precision medicine approach for a biomarker observed in up to 50% of advanced NSCLC patients.
  • This validated companion diagnostic complements NeoGenomics' broader PanTracer™ portfolio, enhancing comprehensive biomarker profiling capabilities for lung cancer treatment decisions.

AstraZeneca Showcases Groundbreaking Cancer Research at ASCO 2025 with Two Plenary Presentations

OncologyTargeted TherapyPrecision MedicineRare Disease
  • AstraZeneca will present over 80 abstracts at ASCO 2025, including two plenary presentations featuring camizestrant for HR-positive breast cancer and IMFINZI for early gastric cancer, marking their seventh consecutive year with plenary data.
  • The SERENA-6 trial is the first positive Phase III study for a next-generation oral SERD in first-line HR-positive breast cancer, pioneering the use of circulating tumor DNA to guide treatment decisions.
  • DESTINY-Breast09 data shows ENHERTU plus pertuzumab is the first treatment in over a decade to demonstrate superiority over standard care in first-line HER2-positive metastatic breast cancer.

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

NCT02564900CompletedPhase 1
Daiichi Sankyo Co., Ltd.
Posted 9/1/2015

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

NCT04924608Active, Not RecruitingPhase 3
AstraZeneca
Posted 11/19/2021

Genomic Testing Emerges as Critical Tool in Brain Cancer Treatment, Experts Emphasize

OncologyTargeted TherapyDrug Approval
  • Comprehensive genomic profiling is crucial for brain cancer patients, enabling personalized treatment approaches and identification of actionable mutations like NTRK fusions, according to Dr. Manmeet Ahluwalia.
  • The recent FDA approval of vorasidenib (Voranigo) for IDH-mutant gliomas represents a breakthrough in targeted therapy for brain tumors and provides hope for developing additional brain-penetrating drugs.
  • Clinical trials remain the optimal treatment option for aggressive brain cancers like glioblastoma, with increasing availability in both academic centers and larger community practices.

Novel IL-2 Derivative Shows Complete Remission in Advanced Skin Cancer Patient After One Year

OncologyTargeted Therapy
• A 73-year-old patient with advanced cutaneous squamous cell carcinoma has remained cancer-free for over a year following treatment with WTX-124, a novel conditionally activated IL-2 pro-drug, in a clinical trial at HonorHealth Research Institute.
• The investigational drug is engineered to remain inactive until it reaches the tumor microenvironment, potentially delivering the benefits of IL-2 therapy with significantly reduced toxicity compared to conventional treatments.
• This breakthrough offers new hope for the nearly 40,000 U.S. patients annually who develop advanced cutaneous squamous cell carcinoma, particularly those who have failed standard treatments including checkpoint inhibitor therapy.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.